The Efficacy of Daily Salmon Oil for Adult Type 2 Asthma: An Exploratory Randomized Double-Blind Trial.

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL

Marine Drugs Pub Date : 2025-08-15 DOI:10.3390/md23080328

Katarina Mølsæter, Kjetil Roth, Tor Åge Myklebust, Erland Hermansen, Dave Singh, Crawford Currie, Dag Arne Lihaug Hoff

{"title":"The Efficacy of Daily Salmon Oil for Adult Type 2 Asthma: An Exploratory Randomized Double-Blind Trial.","authors":"Katarina Mølsæter, Kjetil Roth, Tor Åge Myklebust, Erland Hermansen, Dave Singh, Crawford Currie, Dag Arne Lihaug Hoff","doi":"10.3390/md23080328","DOIUrl":null,"url":null,"abstract":"Asthma is a heterogeneous chronic respiratory condition with distinct inflammatory phenotypes, including type 2-driven eosinophilic asthma. This randomized, double-blind, placebo-controlled exploratory trial investigated the effects of OmeGO®, on respiratory outcomes in adults with type 2 asthma. Over a 20-week period, 66 participants received 6 g per day of either OmeGO® (≥120 mg eicosapentaenoic acid (EPA), ≥180 mg docosahexaenoic acid (DHA)), or placebo. The key outcome was a composite score of moderate and severe exacerbation events. Asthma control was assessed using the Asthma Control Questionnaire-5-item (ACQ5) and the Global Initiative for Asthma (GINA) criteria. The median time to the first composite event was 37 days (95% CI 9-47) in the OmeGO group and 15 days (95% CI 12-33) in the placebo group (p = 0.347); 73% of the participants in the OmeGO experienced at least one exacerbation compared to 82% in the placebo group (p = 0.347). The weekly frequence of composite events was 0.36 per day in the OmeGO group and 0.32 in the placebo group (p = 0.777). Even though there are no differences in the exacerbation rates between groups, the time to first composite event should be further explored.","PeriodicalId":18222,"journal":{"name":"Marine Drugs","volume":"23 8","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387695/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marine Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/md23080328","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Asthma is a heterogeneous chronic respiratory condition with distinct inflammatory phenotypes, including type 2-driven eosinophilic asthma. This randomized, double-blind, placebo-controlled exploratory trial investigated the effects of OmeGO^®, on respiratory outcomes in adults with type 2 asthma. Over a 20-week period, 66 participants received 6 g per day of either OmeGO^® (≥120 mg eicosapentaenoic acid (EPA), ≥180 mg docosahexaenoic acid (DHA)), or placebo. The key outcome was a composite score of moderate and severe exacerbation events. Asthma control was assessed using the Asthma Control Questionnaire-5-item (ACQ5) and the Global Initiative for Asthma (GINA) criteria. The median time to the first composite event was 37 days (95% CI 9-47) in the OmeGO group and 15 days (95% CI 12-33) in the placebo group (p = 0.347); 73% of the participants in the OmeGO experienced at least one exacerbation compared to 82% in the placebo group (p = 0.347). The weekly frequence of composite events was 0.36 per day in the OmeGO group and 0.32 in the placebo group (p = 0.777). Even though there are no differences in the exacerbation rates between groups, the time to first composite event should be further explored.

Abstract Image

查看原文本刊更多论文

每日鲑鱼油治疗成人2型哮喘的疗效：一项探索性随机双盲试验。

哮喘是一种异质性慢性呼吸系统疾病，具有不同的炎症表型，包括2型驱动的嗜酸性哮喘。这项随机、双盲、安慰剂对照的探索性试验研究了omega®对成人2型哮喘患者呼吸结局的影响。在20周的时间里，66名参与者每天接受6克omega®（≥120毫克二十碳五烯酸（EPA），≥180毫克二十二碳六烯酸（DHA））或安慰剂。主要结局是中度和重度恶化事件的综合评分。采用哮喘控制问卷5项（ACQ5）和全球哮喘倡议（GINA）标准评估哮喘控制。omega组发生第一次复合事件的中位时间为37天（95% CI 9-47），安慰剂组为15天（95% CI 12-33）（p = 0.347）；73%的omega组参与者经历了至少一次恶化，而安慰剂组的这一比例为82% （p = 0.347）。omega组每周复合事件发生频率为0.36次/天，安慰剂组为0.32次/天（p = 0.777）。尽管两组间急性加重率无差异，但发生首次复合事件的时间仍需进一步探讨。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Marine Drugs 医学-医药化学

CiteScore

9.60

自引率

14.80%

发文量

671

审稿时长

1 months

期刊介绍： Marine Drugs (ISSN 1660-3397) publishes reviews, regular research papers and short notes on the research, development and production of drugs from the sea. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible, particularly synthetic procedures and characterization information for bioactive compounds. There is no restriction on the length of the experimental section.